Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.
about
Heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor in normal and neoplastic hematopoiesisIntratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategiesTargeting paraprotein biosynthesis for non-invasive characterization of myeloma biology.NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma.The inflammatory chemokine CCL5 and cancer progressionEuropean Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.Preclinical models of multiple myeloma: a critical appraisal.Sorafenib for the treatment of multiple myeloma.CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.From CLL to Multiple Myeloma - Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration.Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.
P2860
Q26852845-FF09BE7B-698A-4348-B95D-68F2741F3FF8Q27302313-E9351C75-C56E-4687-A54A-614236A5E495Q35078496-EE9059EC-A3D8-4AA4-825A-2F5DF9B685BEQ35175289-5619AB05-5727-40C1-BBD5-2DEB65A29430Q35740455-DE6EC314-A1F8-4110-ABA8-FB89BEF566D8Q35781619-2DCF8235-DCF0-430A-9AEB-3C6FF708C22BQ37541911-77EF6B3B-6769-4DAC-9E00-2D6D49130CE4Q37552008-62480B7A-C5CD-4CA8-B39B-07140C934BEFQ38112468-E2AD4875-EE14-4991-9E48-94D94B393B5DQ38783055-E35FDBAF-8694-4D9B-96C3-9D9A2E2FF8F6Q48188365-FE24D586-A860-4A35-A8BA-451EF696040DQ53303327-B589D24A-BD6A-43E9-B4A7-95638573549DQ55021572-159BF315-CF6C-43B2-AF52-C2CDB4494CF3
P2860
Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Potent in vitro and in vivo ac ...... hrough actin depolymerization.
@en
Potent in vitro and in vivo ac ...... hrough actin depolymerization.
@nl
type
label
Potent in vitro and in vivo ac ...... hrough actin depolymerization.
@en
Potent in vitro and in vivo ac ...... hrough actin depolymerization.
@nl
prefLabel
Potent in vitro and in vivo ac ...... hrough actin depolymerization.
@en
Potent in vitro and in vivo ac ...... hrough actin depolymerization.
@nl
P2093
P2860
P356
P1476
Potent in vitro and in vivo ac ...... hrough actin depolymerization.
@en
P2093
Dagmar Wider
Dominik Schnerch
Gabriele Ihorst
Johannes Waldschmidt
Josefina Udi
Julia Schüler
Monika Engelhardt
Ralph Wäsch
P2860
P304
P356
10.1111/BJH.12226
P407
P577
2013-02-06T00:00:00Z